List of Excipients in Branded Drug REZVOGLAR KWIKPEN

REZVOGLAR KWIKPEN Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Rezvoglar KwikPen is insulin glargine-yfgn, a 100 units/mL long-acting insulin biosimilar to Lantus, supplied in a disposable prefilled pen. Its excipient system is commercially important because it supports insulin stability, zinc-mediated hexamer formation, antimicrobial protection, acidic pH control, and compatibility with the pen container. The main opportunity is not a radically new formulation. It is lower-cost manufacturing, reliable supply, device usability, market access, and differentiated delivery economics within the U.S. basal-insulin market.

What excipients are used in Rezvoglar KwikPen?

Rezvoglar uses a conventional insulin glargine formulation with a limited excipient system. The formulation is acidic and becomes less soluble after injection into neutral subcutaneous tissue, producing the intended prolonged-release profile.

Component	Function in Rezvoglar
Insulin glargine-yfgn	Active pharmaceutical ingredient
Glycerol	Tonicity adjustment and formulation stabilization
Metacresol	Antimicrobial preservative and protein-stability component
Zinc oxide	Zinc source that supports insulin hexamer formation and aggregation control
Hydrochloric acid	pH adjustment
Sodium hydroxide	pH adjustment
Water for injection	Vehicle

Rezvoglar has a pH of approximately 4.0. The KwikPen contains 3 mL of solution at 100 units/mL, equivalent to 300 units per pen. Each pen is intended for single-patient use and delivers doses in 1-unit increments. The excipient profile is disclosed in the FDA prescribing information and is materially aligned with the established insulin glargine formulation used for Lantus and other insulin glargine products (FDA, 2023a; FDA, 2023b).

Why is metacresol important?

Metacresol provides antimicrobial protection for a multidose insulin pen. It also interacts with insulin molecules and can affect physical stability. Reducing metacresol can create microbiological and aggregation risks. Increasing it can affect tolerability, protein stability, extractables and leachables, and container compatibility.

For a commercial insulin product, metacresol supply and quality control are more important than the low mass of the ingredient might suggest. The manufacturer must control:

• Assay and impurity profile
• Batch-to-batch concentration
• Interaction with elastomeric components
• Protein aggregation over shelf life
• Preservative effectiveness
• Local injection-site tolerability

What is the role of zinc oxide?

Zinc supports the formation of insulin glargine hexamers. The hexameric state reduces the rate of diffusion and contributes to the prolonged pharmacodynamic profile after subcutaneous administration. Zinc concentration is therefore a critical quality attribute rather than a simple inactive ingredient.

Changes in zinc level, particle behavior, or source quality can affect:

• Insulin association and dissociation
• Subvisible particle formation
• Potency and release testing
• Stability under temperature stress
• Comparability with the reference product

A reformulation that changes zinc chemistry or concentration would require extensive analytical and clinical comparability work.

How does the Rezvoglar formulation support commercial positioning?

Rezvoglar’s excipient strategy is primarily a risk-control strategy. It uses established ingredients and a reference-aligned composition rather than novel excipients. That approach reduces formulation differentiation but improves regulatory and manufacturing predictability.

Manufacturing advantages

The formulation has several commercial advantages:

1. The excipients are established pharmaceutical ingredients with existing supply chains.
2. The formulation does not depend on a novel stabilizer or proprietary delivery polymer.
3. The product can use conventional liquid insulin manufacturing and aseptic filling.
4. Analytical comparability is easier when the formulation remains close to the reference product.
5. The same general excipient architecture can support production at scale.

The main manufacturing barriers are not the cost of glycerol or sodium hydroxide. They are insulin active-ingredient production, sterile processing, aseptic fill-finish, container closure performance, pen assembly, cold-chain management, and regulatory release testing.

Container and device compatibility

The excipient system must be evaluated with:

• Cartridge glass
• Pen plunger and stopper elastomers
• Needle interface components
• Adhesives and printed materials
• Lubricants and silicone oil
• Primary-container extractables and leachables

Metacresol and acidic pH can influence elastomer compatibility. Zinc-containing protein formulations can be sensitive to surface interactions and particulate formation. For a prefilled pen, the formulation and device cannot be developed independently.

What commercial opportunities exist for Rezvoglar excipients?

The largest opportunities are indirect. Suppliers are more likely to create value through quality, redundancy, and formulation-support services than through a new excipient product.

High-value excipient opportunities

Opportunity	Commercial rationale	Entry difficulty
Qualified metacresol supply	Supports preservative control and supply continuity	Medium
Pharmaceutical-grade glycerol	Low-cost but high-volume and critical to formulation consistency	Low to medium
Zinc raw-material qualification	Supports insulin association and product comparability	Medium
Extractables and leachables testing	Required for pen and cartridge compatibility	Medium
Protein aggregation analytics	Supports stability and biosimilar comparability	High
Cold-chain stability programs	Reduces product loss and distribution risk	Medium
Alternative preservative research	Could support future multidose products, but has high regulatory risk	High
Low-waste pen systems	Improves payer and patient economics	High

A supplier that can offer dual-source qualification, tight elemental impurity control, and insulin-specific compatibility data may obtain a stronger position than a supplier offering the lowest nominal excipient price.

Could Rezvoglar support a preservative-free product?

A preservative-free multidose version would face substantial technical and regulatory barriers. A multidose pen must prevent microbial growth after repeated use. Removing metacresol would require an alternative sterility-control strategy, a single-use presentation, a redesigned device, or a different packaging architecture.

Potential alternatives include:

• Single-dose cartridges
• Unit-dose syringes
• Aseptic disposable reservoirs
• Integrated antimicrobial materials
• Shorter in-use periods
• Device systems that limit repeated exposure

These approaches would change the product’s use pattern and could require a new regulatory submission. They are more relevant to future platform development than to near-term Rezvoglar lifecycle management.

What is the FDA regulatory status of Rezvoglar?

Rezvoglar is a biologic approved under the U.S. biosimilar pathway. The FDA approved insulin glargine-yfgn in December 2021. In July 2023, the FDA approved Rezvoglar as interchangeable with Lantus, permitting pharmacy-level substitution subject to state law and payer policy (FDA, 2021; FDA, 2023c).

Regulatory item	Status
Active ingredient	Insulin glargine-yfgn
Reference product	Lantus, insulin glargine
FDA pathway	Section 351(k) biosimilar application
Dosage form	Injectable solution in prefilled pen
Strength	100 units/mL
Interchangeability	FDA-designated interchangeable with Lantus
Product type	Biologic, not a conventional small-molecule generic

Interchangeability provides a commercial advantage over a biosimilar without that designation. It does not automatically guarantee substitution in every state or produce preferred formulary placement. Payers still evaluate net price, rebates, supply reliability, patient support, and contracting terms.

What patents protect Rezvoglar and Lantus?

Rezvoglar is not governed by the same Orange Book framework used for small-molecule drugs. Biologic patent information is principally evaluated through the Purple Book, publicly available patent disclosures, BPCIA procedures, and ordinary patent litigation records.

Lantus-related patent protection has historically included claims directed to insulin glargine, formulations, manufacturing processes, delivery systems, and methods of treatment. Many early composition and formulation rights have expired or reached the end of their practical exclusion period. Later patents can still create litigation risk if they claim specific devices, concentrations, methods of use, or manufacturing steps.

Rezvoglar’s commercial protection is therefore based less on a conventional Orange Book patent listing and more on:

• Biosimilar approval and interchangeability
• Manufacturing know-how
• Quality systems
• Pen-device design
• Supply contracts
• Payer access
• Production scale
• Regulatory compliance

Are Paragraph IV challenges relevant to Rezvoglar?

No. A Paragraph IV certification applies to an abbreviated new drug application for a small-molecule drug listed in the Orange Book. Rezvoglar was approved as a biosimilar under section 351(k), not as an ANDA product.

A competing insulin glargine product would generally use a biosimilar pathway, a different biologic pathway, or another applicable statutory route. Patent disputes could still occur, but they would not normally be characterized as a conventional Paragraph IV challenge to Rezvoglar.

What biosimilar and generic entry risks affect Rezvoglar?

Rezvoglar faces competition from multiple insulin glargine products and from other basal insulins. The relevant competitors include:

• Lantus, the reference insulin glargine product
• Basaglar, insulin glargine
• Semglee, insulin glargine-yfgn, including interchangeable versions
• Toujeo, concentrated insulin glargine U-300
• Tresiba, insulin degludec
• Levemir, insulin detemir, where commercially available
• Lower-priced human NPH insulin

Biosimilar competition is particularly strong because insulin is a high-volume chronic therapy with significant payer sensitivity. Products with interchangeable status can obtain a practical substitution advantage. Products without interchangeability can still compete through rebates, formulary placement, and lower list prices.

The principal risks are:

Risk	Effect on Rezvoglar
Additional interchangeable insulin glargine products	Price compression and pharmacy substitution
Payer-preferred competitor	Lower utilization despite clinical similarity
Supply disruption	Loss of formulary confidence
Device complaints	Higher pharmacovigilance and replacement costs
Manufacturing deviation	Batch release delays or shortage exposure
Competing concentrated basal insulin	Segmentation by dose volume and patient need
Human insulin price competition	Pressure in cost-sensitive channels

How does Rezvoglar compare with competing insulin glargine products?

Product	Molecule	Strength	Delivery profile	Commercial differentiation
Rezvoglar KwikPen	Insulin glargine-yfgn	U-100	Long acting	Interchangeable biosimilar, Lilly/Boehringer portfolio
Lantus SoloStar	Insulin glargine	U-100	Long acting	Reference product and established brand
Basaglar KwikPen	Insulin glargine	U-100	Long acting	Lower-cost insulin glargine competitor
Semglee	Insulin glargine-yfgn	U-100	Long acting	Biosimilar and interchangeable positioning
Toujeo SoloStar	Insulin glargine	U-300	Longer and lower-volume delivery	Concentrated formulation
Tresiba FlexTouch	Insulin degludec	U-100/U-200	Ultra-long acting	Different molecule and dosing profile

Rezvoglar is most directly comparable to Lantus, Basaglar, and Semglee. Its principal differentiation is not an excipient innovation. It is the combined package of interchangeable status, pen presentation, manufacturing scale, and contracting strategy.

What formulation patents could create future commercial value?

Future patent opportunities would likely focus on formulation-device combinations and manufacturing performance rather than on the basic excipient list.

Potential patentable areas

• Improved insulin glargine stability under temperature excursions
• Reduced aggregation during pen use
• Lower extractables and leachables from cartridge components
• Enhanced in-use stability after repeated dose withdrawal
• Alternative zinc-control systems
• Reduced preservative concentration with maintained antimicrobial protection
• Improved low-temperature and high-temperature shipping stability
• Device designs that reduce residual volume
• Formulations optimized for concentrated insulin delivery
• Manufacturing processes that improve yield or reduce particulates

A patent claim directed only to glycerol, metacresol, zinc, water, and pH adjustment would face substantial prior-art exposure. Stronger protection would combine composition ranges with measurable performance outcomes, such as improved stability, lower aggregation, or defined device compatibility.

What licensing opportunities exist around Rezvoglar?

Rezvoglar was developed through the insulin collaboration between Eli Lilly and Boehringer Ingelheim. Lilly commercializes Rezvoglar in the United States, while Boehringer Ingelheim has participated in the development and commercialization relationship for insulin products (Lilly, 2023).

Potential licensing targets include:

• Pen-device technology
• Cartridge and elastomer systems
• Insulin stabilization analytics
• Cold-chain monitoring
• Alternative fill-finish capacity
• Regional manufacturing rights
• Biosimilar development platforms
• Digital adherence and dose-tracking systems

The most attractive licensing opportunities are likely to involve platform capabilities that can be reused across insulin products rather than a single excipient patent.

What is the revenue exposure for Rezvoglar?

Eli Lilly does not generally disclose Rezvoglar revenue as a separate, fully reported product line in its principal public financial statements. Sales are typically considered within broader insulin or diabetes-product reporting. As a result, product-specific revenue, gross margin, and payer-level net price cannot be reliably calculated from public company reporting alone.

Commercial exposure is still material because basal insulin is a chronic, high-volume category. Revenue depends on:

• Number of treated patients
• Formulary tier
• Rebate intensity
• Interchangeable substitution
• Government and commercial payer mix
• Pen utilization
• Supply continuity
• Competitive pricing from Semglee, Basaglar, and Lantus

The excipient cost is a small portion of total product economics. The larger value drivers are active pharmaceutical ingredient yield, sterile fill-finish, device assembly, rebates, distribution, and market access.

What generic launch scenarios exist for Rezvoglar?

Rezvoglar is already a lower-cost biologic competitor, so future erosion is more likely to occur through competing biosimilars and formulary displacement than through a traditional generic launch.

Scenario 1: Stable interchangeable competition

Rezvoglar maintains volume through interchangeability and payer contracts. Excipient costs remain controlled, and the company protects margins through scale and supply reliability.

Scenario 2: Multiple interchangeable insulin glargine products

Additional interchangeable products increase pharmacy-level substitution and intensify price competition. Product quality, availability, and contracting become decisive.

Scenario 3: Concentrated basal-insulin migration

Some patients shift toward U-200 or U-300 products because of dose volume, injection burden, or clinical preference. Rezvoglar remains relevant for U-100 demand but loses selected high-dose segments.

Scenario 4: Device-led differentiation

A competitor introduces a pen with improved dose feedback, lower residual volume, connected functionality, or easier handling. This could create switching pressure even when the underlying insulin and excipient system are similar.

Scenario 5: Supply-driven share transfer

A shortage or manufacturing interruption at a competitor can produce rapid volume gains for Rezvoglar. The reverse is also true. Redundant excipient and fill-finish sources are therefore commercially important.

How strong is the Rezvoglar patent and formulation estate?

Rezvoglar’s strongest commercial protections are regulatory and operational rather than a standalone novel-excipient patent estate. The product benefits from FDA interchangeability, Lilly’s manufacturing infrastructure, the KwikPen platform, and the established clinical role of insulin glargine.

The estate is weaker if evaluated solely on novel formulation exclusivity because the core excipient architecture is mature and closely related to prior insulin glargine products. It is stronger when evaluated as a combined product system involving:

• Insulin glargine-yfgn production
• Biosimilar comparability data
• Pen-device integration
• Quality-control methods
• Manufacturing know-how
• Supply-chain scale
• Payer and pharmacy access

Key Takeaways

• Rezvoglar KwikPen uses a conventional insulin glargine excipient system based on glycerol, metacresol, zinc oxide, pH adjusters, and water for injection.
• Metacresol, zinc, acidic pH, and container compatibility are the principal formulation-control issues.
• Excipient cost is unlikely to determine commercial success; manufacturing yield, fill-finish, device economics, rebates, and supply reliability matter more.
• Rezvoglar is an interchangeable biosimilar, not an Orange Book generic subject to a Paragraph IV certification.
• Its main competitive threats are Semglee, Basaglar, Lantus, concentrated insulin glargine products, and other basal insulins.
• The best future IP opportunities combine excipients with stability performance, device compatibility, manufacturing controls, or concentrated delivery.
• Product-specific Rezvoglar revenue is not separately disclosed in a way that supports a reliable public estimate.

FAQs

Can Rezvoglar use the same excipients as Lantus?

Yes. Biosimilar development can use a formulation closely aligned with the reference product. Rezvoglar’s disclosed excipient profile is consistent with the established insulin glargine formulation architecture.

Is metacresol a patentable commercial differentiator for Rezvoglar?

Metacresol alone is unlikely to provide strong exclusivity because it is a well-established pharmaceutical preservative. Commercially useful protection would more likely involve a specific concentration range, stability result, container system, or device combination.

Does Rezvoglar require cold-chain distribution?

Yes. Rezvoglar requires refrigerated storage before use and controlled storage during in-use periods under the FDA-approved labeling. Temperature excursion management is a meaningful supply-chain and quality opportunity.

Can pharmacies automatically substitute Rezvoglar for Lantus?

Interchangeability supports pharmacy-level substitution, but actual substitution depends on state law, payer rules, pharmacy policy, and product availability.

Could a new excipient create a superior insulin glargine product?

Potentially, but a new excipient would create a substantial regulatory burden. The sponsor would need to establish safety, compatibility, stability, comparability, immunogenicity risk, and preservation performance.

References

Eli Lilly and Company. (2023). Annual report 2023. https://investor.lilly.com

U.S. Food and Drug Administration. (2021). FDA approves first interchangeable biosimilar insulin product. https://www.fda.gov

U.S. Food and Drug Administration. (2023a). Rezvoglar (insulin glargine-yfgn) prescribing information. https://pi.lilly.com

U.S. Food and Drug Administration. (2023b). Lantus (insulin glargine injection) prescribing information. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2023c). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-and-interchangeable-products